Monday 05 December 2016 12:59 pm Australian students recreate drug for $2 per dose By: Courtney Goldsmith Share Facebook Share on Facebook X Share on Twitter LinkedIn Share on LinkedIn WhatsApp Share on WhatsApp Email Share on Email Add as a preferred source on Google NULL Stay in the know Three daily briefings with the key market moves and top business and political stories. SUBSCRIBE HERE
AviadoBio Presents New Safety and Biomarker Data from the Phase 1/2 ASPIRE-FTD Trial at the International Conference on Frontotemporal Dementias Business Wire
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research Business Wire
Alentis and PinotBio Announce Collaboration to Develop Next-Generation ADCs Targeting claudin-1 Business Wire
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) Business Wire